All companies
Vitrafy Life Sciences logo

What smart money is saying about Vitrafy Life SciencesAustralia flag

VFY.AX · Technology · Software - Infrastructure · Market cap $137M

1 fund in our archive has pitched Vitrafy Life Sciences — most recently Ryder Capital Limited in September 2026.

Company profile

Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.

Get an email when a fund buys, sells or pitches it

Summarize with Warren AI
1
Reported positions
0
Bought
0
Sold
1
Letter

Position history

Every position in Vitrafy Life Sciences on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.

Fund letters reporting a position in Vitrafy Life Sciences, by quarter
QuarterLettersBoughtSoldTheses
Q3 20261001

Fund activity · 1 position

Fund coverage · 1 thesis

  • Ryder Capital Limited
    September 2026

    Vitrafy Life Sciences is building validation across blood banking and cell therapy markets, with partnerships and funding supporting near-term commercialization.

    Read the full thesis

Read every full thesis on Vitrafy Life Sciences

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans→
Share this ledger